One of the details of NVIDIA’s investment is a $50 million investment in Recursion Pharmaceuticals. This notable investment was announced on July 12, 2023, and Recursion intends to use the funds to train artificial intelligence (AI) models. These models focus on leveraging biological and chemical data to accelerate drug discovery. Through this investment, NVIDIA purchased more than 7.7 million shares of Recursion’s Class A common stock, securing an approximately 4% stake [❞] [❞] [❞].

Recursion plans to collaborate with NVIDIA to create an underlying model on an unprecedented scale in biology and chemistry. The company will leverage its vast proprietary biological and chemical datasets in NVIDIA DGX™ Cloud to accelerate underlying model training and commercially license or distribute them through NVIDIA’s BioNeMo, Generative AI cloud service for drug discovery [❞] .

Recursion’s AI platform consists of a vast native biological and chemical dataset of over 23 petabytes, Recursion Data Universe containing tens of billions of searchable biological and chemical inferences. This enables millions of wet experiments each week [❞] .

These collaborations and investments can be seen as part of NVIDIA’s broader strategy to accelerate innovation in life sciences through AI and cloud computing technologies. Investments in companies like Recursion open up new market opportunities for NVIDIA in the field of drug discovery, and strengthen their commitment to healthcare innovation through AI.